“When we talk about solutions, it is very important to make accurate assessments and create the right expectations. Creating false expectations is not justified by anything; on the contrary, it is immoral,” Mikheil Sarjveladze,  the Georgian Health Minister, addressing the issue of importing Duchenne muscular dystrophy treatment drugs.

He noted that discussions on the availability and procurement of Duchenne treatments require close cooperation with all stakeholders, including parents, patients, and medical experts.

According to Sarjveladze, similar discussions are ongoing in many European countries, where decisions on certain medicines have not yet been finalized.

“We are waiting with great interest, hope, and goodwill for all questions related to these medications to be answered and for European countries to begin procurement,” he said.

The minister added that decisions taken by individual countries should not be automatically considered definitive for the rest of Europe, as evaluations and regulatory processes are still underway.

Sarjveladze also said the Ministry of Health has been studying international experience and medical practice related to Duchenne therapies for an extended period.

Referring to his participation in the World Health Assembly in Switzerland, he noted that these issues are being actively discussed across Europe.

“In European countries as well, these matters are being discussed, and decisions are not made until all questions are answered,” he said.

At the same time, Sarjveladze expressed hope that decisions regarding certain medications could be reached in the near future.

“I have great hope that we will soon have the opportunity to make decisions regarding some specific medications,” he added.